Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
Go back to Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)| Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) | Delayed: 52.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $52.48 | 52 Week High | $18.32 | |||
| Open | $39.17 | 52 Week Low | $7.86 | |||
| Day High | $52.48 | P/E | N/A | |||
| Day Low | $52.48 | EPS | $-2.13 | |||
| Volume | 147,551 | |||||
| Mylan Inc. (NASDAQ: MYL) | Delayed: 15.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.86 | 52 Week High | $55.51 | |||
| Open | $10.56 | 52 Week Low | $33.60 | |||
| Day High | $15.86 | P/E | 10.43 | |||
| Day Low | $15.86 | EPS | $1.52 | |||
| Volume | 45,581 | |||||
